title: Adverse response to pegylated interferon therapy in two patients with chronic hepatitis C.
abstract: Pegylated interferons have recently been approved for treatment of hepatitis C. The safety of these formulations is reported to be similar to that of non-pegylated interferon. We present two patients who experienced exacerbations of their liver disease following administration of pegylated interferon alfa-2b. Vigilant monitoring of patients treated with these new agents is recommended.
authors.affiliation: wthomasmd@hotmail.com
authors.forename: William L
authors.initials: WL
authors.lastname: Thomas
authors.forename: Fernando
authors.initials: F
authors.lastname: Ramos
authors.forename: Duane R
authors.initials: DR
authors.lastname: Hospenthal
mesh_terms: D000368:Aged; D000998:Antiviral Agents / Q000009:adverse effects*; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000009:adverse effects*; D011994:Recombinant Proteins
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a